Financings in Brief: Lifecore Biomedical
This article was originally published in The Gray Sheet
Lifecore Biomedical: Net proceeds from secondary offering reach approximately $23 mil. following the purchase of the entire over-allotment option of 330,000 shares by underwriters Piper Jaffray and Needham & Company. The Chaska, Minnesota-based firm has about 10.5 mil. shares outstanding after the offering, completed in October ("The Gray Sheet" Oct. 30, p. 17)...
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.